Cancer Chemotherapy and Pharmacology

, Volume 72, Issue 6, pp 1299–1304 | Cite as

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

  • Kohei Motoshima
  • Yoichi Nakamura
  • Kazumi Sano
  • Yoji Ikegami
  • Takaya Ikeda
  • Kosuke Mizoguchi
  • Shinnosuke Takemoto
  • Minoru Fukuda
  • Seiji Nagashima
  • Tetsuya Iida
  • Kazuhiro Tsukamoto
  • Shigeru Kohno
Original Article
First Online:
Received:
Accepted:

Abstract

Background

We conducted a phase II trial of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and evaluated the relationship between plasma concentration and efficacy of erlotinib.

Methods

Patients who were previously treated but naive to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), with advanced NSCLC harboring EGFR mutations, were enrolled. Erlotinib was given at 150 mg once daily until disease progression. The primary end point was objective response rate (ORR). Plasma trough levels of erlotinib were measured on Days 2 (D2) and 8 (D8) by high-performance liquid chromatography.

Results

In total, 29 patients were enrolled from September 2008 to January 2011. ORR was 61.5 % (95 % confidence interval [CI] 40.57–79.8) of 26 assessable patients. The median progression-free survival (PFS) and overall survival (OS) were 6.3 months and 16.9 months, respectively. Skin rash was observed in 24 patients, mostly at grade 1 or 2. Grade 2 pneumonitis was observed in one patient. We collected blood samples from 16 patients. The median PFS of the high and low D8/D2 ratio group was 11.2 months and 5.7 months, respectively (p = 0.044, hazard ratio = 0.301, 95 % CI 0.094–0.968).

Conclusion

Erlotinib showed an ORR comparable to that seen in previous studies for patients with NSCLC harboring EGFR mutations, although response, the primary end point, did not reach the predetermined threshold level. The D8/D2 ratio of erlotinib plasma trough levels might be a predictive factor for PFS.

Keywords

Non-small-cell lung cancer Erlotinib Chemotherapy Pharmacokinetics EGFR mutation 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

We confirm that this report has not been published or presented elsewhere, either in whole or in part, and that it is not under consideration by another journal. All authors have approved the content and agree with its submission. No financial support was received for this publication, and neither my co-authors nor I have any conflict of interest to declare.

References

  1. 1.
    Schlessinger J (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110:669–672PubMedCrossRefGoogle Scholar
  2. 2.
    Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–15PubMedCrossRefGoogle Scholar
  3. 3.
    Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRefGoogle Scholar
  4. 4.
    Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRefGoogle Scholar
  5. 5.
    Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246PubMedCrossRefGoogle Scholar
  6. 6.
    Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742PubMedCrossRefGoogle Scholar
  7. 7.
    Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73PubMedCrossRefGoogle Scholar
  8. 8.
    Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792PubMedCrossRefGoogle Scholar
  9. 9.
    Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043PubMedCrossRefGoogle Scholar
  10. 10.
    Yano S, Wang W, Li Q et al (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68:9479–9487PubMedCrossRefGoogle Scholar
  11. 11.
    Nakamura Y, Sano K, Soda H et al (2010) Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol 5:1404–1409PubMedCrossRefGoogle Scholar
  12. 12.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  13. 13.
    Uesugi T, Sano K, Uesawa Y et al (1997) Ion-pair reversed-phase high-performance liquid chromatography of adenine nucleotides and nucleoside using triethylamine as a counterion. J Chrom B Biomed Sci Appl 703:63–74CrossRefGoogle Scholar
  14. 14.
    Hidalgo M, Siu LL, Nemunaitis J et al (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267–3279PubMedGoogle Scholar
  15. 15.
    Yamamoto N, Horiike A, Fujisaka Y et al (2008) Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 61:489–496PubMedCrossRefGoogle Scholar
  16. 16.
    Rosell R, Molina MA, Costa C et al (2011) Pretreatment EGFR T790 M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 17:1160–1168PubMedCrossRefGoogle Scholar
  17. 17.
    Hu JC, Sadeghi P, Pinter-Brown LC et al (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56:317–326PubMedCrossRefGoogle Scholar
  18. 18.
    Wheatley-Price P, Ding K, Seymour L et al (2008) Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26:2350–2357PubMedCrossRefGoogle Scholar
  19. 19.
    Yeo WL, Riely GJ, Yeap BY et al (2010) Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 5:1048–1053PubMedGoogle Scholar
  20. 20.
    Han SW, Kim TY, Jeon YK et al (2006) Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12:2538–2544PubMedCrossRefGoogle Scholar
  21. 21.
    Yano S, Yamada T, Takeuchi S et al (2011) Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6:2011–2017PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Kohei Motoshima
    • 1
  • Yoichi Nakamura
    • 1
  • Kazumi Sano
    • 2
  • Yoji Ikegami
    • 2
  • Takaya Ikeda
    • 1
  • Kosuke Mizoguchi
    • 1
  • Shinnosuke Takemoto
    • 1
  • Minoru Fukuda
    • 3
  • Seiji Nagashima
    • 1
  • Tetsuya Iida
    • 1
  • Kazuhiro Tsukamoto
    • 4
  • Shigeru Kohno
    • 1
  1. 1.Second Department of Internal MedicineNagasaki University School of MedicineNagasakiJapan
  2. 2.Department of Drug Metabolism and DispositionMeiji Pharmaceutical UniversityTokyoJapan
  3. 3.Department of Respiratory MedicineJapanese Red-Cross Nagasaki Atomic Bomb HospitalNagasakiJapan
  4. 4.Department of PharmacotherapeuticsNagasaki University Graduate School of Biomedical SciencesNagasakiJapan

Personalised recommendations